收费全文 | 2216篇 |
免费 | 173篇 |
国内免费 | 3篇 |
耳鼻咽喉 | 25篇 |
儿科学 | 81篇 |
妇产科学 | 47篇 |
基础医学 | 289篇 |
口腔科学 | 29篇 |
临床医学 | 405篇 |
内科学 | 392篇 |
皮肤病学 | 46篇 |
神经病学 | 211篇 |
特种医学 | 45篇 |
外科学 | 208篇 |
综合类 | 34篇 |
一般理论 | 1篇 |
预防医学 | 236篇 |
眼科学 | 37篇 |
药学 | 152篇 |
中国医学 | 2篇 |
肿瘤学 | 152篇 |
2023年 | 17篇 |
2022年 | 38篇 |
2021年 | 70篇 |
2020年 | 43篇 |
2019年 | 52篇 |
2018年 | 86篇 |
2017年 | 58篇 |
2016年 | 49篇 |
2015年 | 50篇 |
2014年 | 86篇 |
2013年 | 125篇 |
2012年 | 164篇 |
2011年 | 177篇 |
2010年 | 90篇 |
2009年 | 63篇 |
2008年 | 138篇 |
2007年 | 126篇 |
2006年 | 141篇 |
2005年 | 159篇 |
2004年 | 134篇 |
2003年 | 105篇 |
2002年 | 97篇 |
2001年 | 16篇 |
2000年 | 17篇 |
1999年 | 14篇 |
1998年 | 29篇 |
1997年 | 11篇 |
1996年 | 12篇 |
1995年 | 12篇 |
1994年 | 6篇 |
1993年 | 9篇 |
1992年 | 6篇 |
1991年 | 8篇 |
1990年 | 10篇 |
1989年 | 8篇 |
1988年 | 10篇 |
1987年 | 14篇 |
1986年 | 6篇 |
1985年 | 14篇 |
1984年 | 10篇 |
1983年 | 16篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 9篇 |
1974年 | 5篇 |
1973年 | 8篇 |
1972年 | 10篇 |
1971年 | 7篇 |
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献The Centers for Disease Control and Prevention (CDC) and 35 partner organizations have engaged in developing an agenda for Preconception Health. A summit was held in June 2005 to discuss the current state of knowledge regarding preconception care and convene a select panel to develop recommendations and action steps for improving the health of women, children, and families through advances in clinical care, public health, and community action. A Select Panel on Preconception Care, convened by CDC, deliberated critical related issues and created refined definition of preconception care. The panel also developed a strategic plan with goals, recommendations, and action steps for improving preconception health. The recommendations and action steps are specific to the implementation of health behavior, access, consumer demand, research, and surveillance activities for monitoring and improving the health of women, children and families. The outcome of the deliberations is the CDC publication of detailed recommendations and action steps in the Morbidity and Mortality Weekly Report series, Recommendations and Reports.
相似文献